The mainstay of current drug therapy is long-acting bronchodilators; several longer acting
inhaled β 2-agonists and muscarinic antagonists (and combinations) are now in …

The mainstay of current drug therapy is long-acting bronchodilators; several longer acting
inhaled β2-agonists and muscarinic antagonists (and combinations) are now in …

COPD, for which cigarette smoking is the major risk factor, remains a worldwide burden.
Current therapies provide only limited short-term benefit and fail to halt progression. A …

Although long-acting bronchodilators have been an important advance for the management
of chronic obstructive pulmonary disease (COPD), these drugs do not deal with the …

There is a pressing need for more effective drug treatments for COPD. New bronchodilators
include a long-acting anticholinergic tiotropium bromide and a dual β 2-dopamine 2 …

Chronic obstructive pulmonary disease (COPD) is a major global health problem which is
increasing throughout the world and a major cause of death. However, current therapies fail …

Chronic obstructive pulmonary disease (COPD) is an increasing global health problem and
cause of death. COPD is a chronic inflammatory disease predominantly affecting small …

No currently available treatments reduce the progression or suppress the inflammation of
chronic obstructive pulmonary disease (COPD). However, with a better understanding of the …

COPD is a major health problem, with patients showing a progressively declining, largely
irreversible, change in lung function. This is associated with chronic airways inflammation …

COPD imposes considerable worldwide burden in terms of morbidity and mortality. In
recognition of this, there is now extensive focus on early diagnosis, secondary prevention …